摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,5S)-7-Chloro-5-(2,3-methylenedioxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid | 179462-58-9

中文名称
——
中文别名
——
英文名称
(3R,5S)-7-Chloro-5-(2,3-methylenedioxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid
英文别名
2-[(3R,5S)-5-(1,3-benzodioxol-4-yl)-7-chloro-1-(2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetic acid
(3R,5S)-7-Chloro-5-(2,3-methylenedioxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid化学式
CAS
179462-58-9
化学式
C23H24ClNO6
mdl
——
分子量
445.9
InChiKey
XUYAGBLPHLZNDP-UYAOXDASSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    85.3
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Benzoxazepine and benzothiazepine derivatives useful as antihypertriglyceridemic agents
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:EP0705607A2
    公开(公告)日:1996-04-10
    An antihypertriglyceridemic composition comprising a compound of formula (I) wherein R1 represents a hydrogen atom or a hydrocarbon group that may be substituted; R2 and R3 may be the same or different and each represents a hydrogen atom, a hydrocarbon group that may be substituted, or a heterocyclic group that may be substituted; X' represents a substituent comprising a carboxyl group that may be esterified, a carbamoyl group that may be substituted, a hydroxyl group that may be substituted, an amino group that may be substituted, or an optionally substituted heterocyclic group having a hydrogen atom that may be deprotonated; ring A represents a benzene ring that may be substituted or a heterocyclic ring that may be substituted; ring J' represents a 7- or 8-membered heterocyclic ring having at most 3 hetero-atoms as ring constituent members; and ring J' may have a further substituent in addition to R1, R2, R3 and X', or a pharmacologically acceptable salt thereof. The composition has a plasma triglyceride concentration-lowering activity, and therefore is useful for the prophylaxis or treatment of hyperlipemia, such as hypertriglyceridemia.
    一种抗高三酸甘油酯组合物,包括化合物(I)的结构式,其中R1代表氢原子或可被取代的碳氢基团;R2和R3可以相同或不同,每个代表氢原子,可被取代的碳氢基团,或可被取代的杂环基团;X'代表取代基,包括可酯化的羧基,可被取代的基甲酰基,可被取代的羟基,可被取代的基,或者是具有可去质子的氢原子的可选取代杂环基团;环A代表可以被取代的苯环或者可以被取代的杂环;环J'代表最多有3个杂原子作为环成员的7-或8-成员杂环,除了R1、R2、R3和X'之外,环J'还可以具有进一步的取代基,或其药学上可接受的盐。该组合物具有降低血浆三酸甘油酯浓度的活性,因此对于预防或治疗高脂血症,如高三酸甘油酯血症,有用。
  • Preventives/remedies for organ functional disorders and organ dysfunction
    申请人:——
    公开号:US20040204500A1
    公开(公告)日:2004-10-14
    The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    本发明提供了一种用于预防或治疗器官功能障碍的药剂、用于预防或治疗器官功能障碍的药剂以及用于预防或治疗肥胖和其中的脱症的药剂,每种药剂均包含具有增加泛醌或其盐或其前药的效果的化合物;以及一种增加泛醌的剂量,包括具有角鲨烷合成酶抑制作用或其盐或前药的化合物。
  • Agent for preventing or treating organ functional disorders and organ dysfunction
    申请人:Sugiyama Yasuo
    公开号:US20060241096A1
    公开(公告)日:2006-10-26
    The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    本发明提供了一种预防或治疗器官功能障碍的药剂、一种预防或治疗器官功能失调的药剂,以及一种预防或治疗肥胖和其代谢障碍的药剂,每种药剂均包含具有增加泛醌或其盐或其前药的效果的化合物;以及一种增加泛醌的药剂,包括具有角鲨烷合酶抑制作用或其盐或其前药的化合物。
  • HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1332763A1
    公开(公告)日:2003-08-06
    A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.
    一种新型高密度脂蛋白胆固醇升高剂,含有一种具有角鲨烯合成酶抑制活性的化合物。
  • PREVENTIVES/REMEDIES FOR ORGAN FUNCTIONAL DISORDERS AND ORGAN DYSFUNCTION
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1407782A1
    公开(公告)日:2004-04-14
    The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    本发明提供了一种用于预防或治疗器官功能紊乱的制剂、一种用于预防或治疗器官功能障碍的制剂和一种用于预防或治疗肥胖症及其脱发症的制剂,其中每种制剂都包含一种具有增加泛醌效果的化合物或其盐或其原药;以及一种增加泛醌的制剂,该制剂包含一种具有角鲨烯合成酶抑制效果的化合物或其盐或其原药。
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)